Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
ALPHARETTA, Ga., Nov. 08, 2016 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, announced that Daniel H. White, Chief Executive Officer and President of Clearside, will present at the 2016 Stifel Healthcare Conference on Wednesday, November 16, 2016 at 3:00pm EST at the Lotte New York Palace in New York, NY.
The presentation will be webcast live and may be accessed by visiting Clearside’s website at http://ir.clearsidebio.com. A replay of the webcast will be available for 30 business days.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly traded, ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and pre-clinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially significant treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, wet age-related macular degeneration and diabetic macular edema. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Contacts Company: Charles Deignan Chief Financial Officer 678-270-4005 [email protected] Investors: Matthew Beck The Trout Group 646-378-2933 [email protected]
